Ustekinumab (Stelara) for Psoriasis
The FDA has approved the use of ustekinumab (Stelara - Centocor Ortho Biotech), an interleukin antagonist given by subcutaneous (SC) injection for treatment of adults with moderate to severe plaque psoriasis. It is the first agent in its class for this indication; the other biologic agents for psoriasis are Tcell or tumor necrosis factor (TNF) inhibitors....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Ustekinumab (Stelara) for Psoriasis
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1330
Article Code: 1330c
Date: January 25, 2010
Volume: 52
Pages: 7-8
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1330
Article Code: 1330c
Date: January 25, 2010
Volume: 52
Pages: 7-8
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)